GlassScriptPhysician profile
Aderonke Oluseye
NPI 1881202406
$2,584.58
in general payments reported to CMS, 2019-2025
46 companies · $918 in 2025
The $918 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $264 · 2022: $393 · 2023: $728 · 2024: $281 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,926.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $339.63 | 2021-2025 | |
| Janssen Biotech, INC. | $175.87 | 2021-2023 | Darzalex, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $156.59 | 2023-2025 | Opdivo |
| Pharmaessentia USA Corporation | $120.17 | 2022-2025 | Besremi |
| Lilly USA, LLC | $118.66 | 2021-2025 | Verzenio, Jaypirca |
| Aveo Pharmaceuticals, INC. | $99.18 | 2021-2025 | Fotivda |
| Genentech USA, INC. | $93.69 | 2022-2025 | Itovebi, Venclexta |
| Astrazeneca Pharmaceuticals LP | $85.41 | 2023-2025 | Calquence |
| Incyte Corporation | $78.35 | 2023-2025 | Monjuvi, Zynyz, Pemazyre |
| Merck Sharp & Dohme LLC | $68.93 | 2023-2025 | Keytruda, Keytruda Qlex |
| Gilead Sciences, INC. | $67.99 | 2023-2025 | Trodelvy |
| Daiichi Sankyo INC. | $67.30 | 2023-2025 | Enhertu, Datroway |
| Genzyme Corporation | $66.56 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.87 | 2022-2023 | Ninlaro |
| Glaxosmithkline, LLC. | $63.79 | 2024-2025 | Ojjaara |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aderonke Oluseye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.